Study of ARO-APOC3 in Adults With Dyslipidemia

Summary

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.

Timeline

Start

2022-07-07

Primary completion

2025-09-22

Completion

2025-09-22

Publications

• Ballantyne CM, Baass A, Rosenson RS, Hegele RA, Nicholls SJ, Vasas S, Clifton P, Lucas KJ, Pall D, Zhou R, Leeper NJ, Hellawell J, Aiyer L, Watts GF, Gaudet D. Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials. Am J Prev Cardiol. 2026 Mar 24;27:101523. doi: 10.1016/j.ajpc.2026.101523. eCollection 2026 Jun.

Drugs

Indications